DAMGO TFA is aμ-opioid receptor(μ-OPR) selective agonist with aK_dof 3.46 nM for native μ-OPR^[1].

DAMGO (1-10 μM) TFA significantly reduces the activation of neuronal Akt and ERK1/2 by CXCL12 and inhibits CXCL12-promoted neuronal survival, but does not down-regulate CXCR4 protein expression^[2].
DAMGO (1 μM) TFA effectively inhibits the prostaglandin E 2 (PGE 2) induced increase in a tetrodotoxin-resistant voltage-gated Na⁺current (TTX-R I_Na), i.e. PGE 2 (1 μM) can increase the TTX-R I_Napeak by 103 % compared to 24.9 % with the addition of DAMGO^[3].

DAMGO (i.v., 0.5-2 mg/kg) TFA can produce significant anti-injury effects on injured paws of male Sprague-Dawley rats weighing 200-225 g in a dose-dependent manner, producing an effective and long-lasting analgesic effect^[4].

627.61

Solid

C₂₈H₃₆F₃N₅O₈

950492-85-0

Tyr-{d-Ala}-Gly-{Me-Phe}-Gly-ol

Y-{d-Ala}-G-{Me-Phe}-G-ol

Room temperature in continental US; may vary elsewhere.

Sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

H₂O : 125 mg/mL(199.17 mM;Need ultrasonic)

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

• 1.

  请依序添加每种溶剂： PBS

  Solubility: 100 mg/mL (159.33 mM); Clear solution; Need ultrasonic